China Universal CNI BIOMEDICINE ETF(159839) Falls 0.83%, Sees Net Inflow of 25.3434 Million Yuan Over the Past 10 Trading Days

NewTimeSpace News, as of 14:37 on April 30, 2026, China Universal Biopharmaceutical ETF (159839) fell 0.83%, with its latest quoted price at 0.36 yuan. Looking at a longer timeframe, as of April 29, 2026, China Universal Biopharmaceutical ETF gained 4.05% over the past month. (The stocks listed above are merely index constituents and do not constitute any specific recommendation.)

In terms of liquidity, China Universal Biopharmaceutical ETF recorded an intraday turnover rate of 2.84%, with a trading volume of 23.9734 million yuan. Over a longer horizon, as of April 29, the ETF's average daily turnover over the past month stood at 33.7099 million yuan.

In terms of share size, China Universal Biopharmaceutical ETF's share count increased by 414 million units over the past year, achieving significant growth, with the new share increment ranking 1/3 among comparable funds. (Data source: Wind)

In terms of capital inflows, the latest net inflow for China Universal Biopharmaceutical ETF was 3.7714 million yuan. Looking at a longer timeframe, over the past ten trading days, there were six days of net inflows, totaling 25.3434 million yuan, with an average daily net inflow of 2.5343 million yuan. (Data source: Wind)

Data shows that leveraged funds continue to position themselves. The latest margin purchase amount for China Universal Biopharmaceutical ETF reached 1.6406 million yuan, and the latest margin balance stood at 29.3320 million yuan. (Data source: Wind)

As of April 29, China Universal Biopharmaceutical ETF's net value increased by 12.41% over the past year. In terms of return capability, as of April 29, 2026, since its inception, the ETF achieved a highest single-month return of 27.69%, a longest consecutive gaining streak of five months with a cumulative gain of 31.17%, and an average return of 5.93% during up months. As of April 29, 2026, the ETF's annualized excess return over its benchmark over the past two years was 0.56%.

In terms of drawdown, as of April 29, 2026, China Universal Biopharmaceutical ETF's relative drawdown versus its benchmark since the beginning of the year was 0.21%.

In terms of fees, China Universal Biopharmaceutical ETF has a management fee rate of 0.50% and a custody fee rate of 0.10%, the lowest fee rates among comparable funds.

In terms of tracking accuracy, as of April 29, 2026, China Universal Biopharmaceutical ETF's one-month tracking error was 0.014%, the highest tracking precision among comparable funds.

China Universal Biopharmaceutical ETF closely tracks the CNI Biopharmaceutical Index. The CNI Biopharmaceutical Index takes listed companies related to the biopharmaceutical industry on the Shanghai, Shenzhen, and Beijing stock exchanges as the sample space, and selects the top 30 securities as index constituents based on a comprehensive ranking of market capitalization and liquidity. It reflects the overall operation of the biopharmaceutical industry and provides the market with index-based investment instruments for this sub-sector.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.